Data Insights

ERSM-5404 by Hibercell for Papillary Renal Cell Carcinoma: Likelihood of Approval

ERSM-5404 is under clinical development by Hibercell and currently in Phase I for Papillary Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ERSM-5404 in Papillary Renal Cell Carcinoma

Data Insights

ERSM-5404 by Hibercell for Renal Cell Carcinoma: Likelihood of Approval

ERSM-5404 is under clinical development by Hibercell and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - ERSM-5404 in Renal Cell Carcinoma

Data Insights

ERSM-5404 by Hibercell for Solid Tumor: Likelihood of Approval

ERSM-5404 is under clinical development by Hibercell and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - ERSM-5404 in Solid Tumor

Data Insights

ERSM-5404 by Hibercell for Small-Cell Lung Cancer: Likelihood of Approval

ERSM-5404 is under clinical development by Hibercell and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - ERSM-5404 in Small-Cell Lung Cancer

Data Insights

ERSM-5404 by Hibercell for Gastric Cancer: Likelihood of Approval

ERSM-5404 is under clinical development by Hibercell and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - ERSM-5404 in Gastric Cancer

Data Insights

ERSM-5404 by Hibercell for Colorectal Cancer: Likelihood of Approval

ERSM-5404 is under clinical development by Hibercell and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - ERSM-5404 in Colorectal Cancer

Data Insights

ERSM-5404 by Hibercell for Non-Small Cell Lung Cancer: Likelihood of Approval

ERSM-5404 is under clinical development by Hibercell and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...